FOR IMMEDIATE RELEASE

MaaT Pharma Presents Product Analysis of its First-in-class High Diversity Microbiome Therapeutic at 2018 EMBO Symposium on The Human Microbiome

Results from *in silico* analysis using MaaT Pharma's data analysis platform, GutPrint, demonstrate therapeutic rationale and manufacturing capabilities of developing a high diversity biological drug product

Lyon, France, September 18, 2018 – MaaT Pharma announced today the presentation of the analysis of MaaT Pharma's lead biotherapeutic, MaaT013, demonstrating its drug product characteristics using MaaT Pharma's proprietary big data analysis platform, GutPrint®. The results of the study form the foundation of MaaT Pharma's approach to create standardized and reproducible high diversity microbiome therapeutics to treat life-threatening diseases. MaaT Pharma's Bioinformatics Manager, Lilia Boucinha, Ph.D. presented the data at the 2018 European Molecular Biology Organization (EMBO) Symposium – The Human Microbiome, being held from September 16 – 19, 2018 at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.

"Alterations in the microbiome, also called dysbiosis, have been implicated in a wide-range of diseases, and re-establishing its function has been scientifically and clinically validated as a therapeutic approach. We have developed our lead biotherapeutic product, MaaT013, based on our fundamental belief that high microbial species richness and diversity are critical to achieving therapeutic impact," said Hervé Affagard, Co-Founder and CEO of MaaT Pharma. "The results we presented today, clearly demonstrate our capabilities to produce a reproducible high diversity cGMP product and we look forward to further evaluating MaaT013 in our ongoing Phase 2 trial in acute Graft-versus-Host Disease patients."

In the presented study MaaT Pharma's proprietary biotherapeutic MaaT013 was evaluated in comparison to a single donor approach using MaaT Pharma's proprietary and validated big data analysis platform GutPrint®. In comparison to single donor samples, MaaT013 showed significantly increased diversity. Most importantly, diversity within the sample batches was less variable and a greater homogeneity between batches was observed compared to single donor samples. Furthermore, the analysis of the MaaT013 samples showed that there was a 58% increase in the number of microbes (richness) compared to single-donor-based FMT products and less than 5% of Proteobacteria, which are known to include pro-inflammatory species. Taken together, these data strongly highlight MaaT Pharma's capabilities to produce a cGMP high diversity drug product for clinical evaluation.

Dr. Joel Doré, Scientific Co-founder of MaaT Pharma and senior author on the poster commented: "Recent publications in *Cell* have demonstrated that a complete microbiome approach is critical to restore a functional microbiome in patients and we are very pleased to have the opportunity to present our novel biotherapeutic approach at the prestigious EMBO Symposium on the human microbiome. We established GutPrint® to assist our development of high microbial diversity - high richness drug products to restore

immune homeostasis and gut barrier integrity in severe diseases and our results give impetus to our rationale for developing a biological drug product which can overcome donor-dependent responses and the limitations of approaches relying on single species or a simple cocktail."

Poster Discussion Session details:

Title: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases
Abstract No: 64
Poster Session: II
Date/Time: September 18, 2018 / 16:30 – 18:30
Location: ATC Helix A and B

The poster will be made available on the company website following the presentation under "News".

About MaaT Pharma

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

Contacts

For MaaT Pharma
Hervé Affagard, CEO
Phone: +33 (0)4 2829 1400
haffagard@maat-pharma.com

Media Requests for MaaT Pharma
Gretchen Schweitzer or Dr. Stephanie May
Trophic Communications
Phone: +49 89 23 88 77 30 or +49 171 185 56 82
E-Mail: may@trophic.eu